AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Treatment of Acne in the Pregnant Patient

Description

Dr. Jeanette Kirai, a professor of dermatology, presented on the treatment of acne in pregnant patients, discussing its prevalence and approaches to manage it safely. Acne is common in pregnancy, affecting about 42% of women, especially those who had previous acne. Treatment is essential for the psychological well-being of patients, and topicals are preferred, with emphasis on using safe options like azelaic acid, clindamycin, and benzoyl peroxide. The talk addressed concerns over systemic medications, reinforcing the importance of considering the pregnancy trimester when prescribing treatments. Dr. Kirai highlighted that while many medications are safe, such as certain antibiotics and hormonal treatments, caution is needed with retinoids and those with potential risks. She also discussed the significance of managing expectations, the importance of lifestyle changes before conception, and collaborations with obstetricians. The presentation concluded with recommendations to continue treating acne during pregnancy, using resources like MotherToBaby.org for further guidance and ensuring that patient education is prioritized.

View more

Conclusions

  • Acne is a common issue during pregnancy, affecting up to 42% of pregnant women, with many experiencing worsened symptoms.
  • Most women with pregnancy-related acne had prior experiences with acne before becoming pregnant.
  • The psychological impact of acne during pregnancy is significant, often leading women to seek treatment for relief.
  • First-line treatments for acne in pregnant women include topical medications like azelaic acid, clindamycin, and benzoyl peroxide, while systemic treatments are considered for severe cases.
  • Certain topical medications, especially those with minimal systemic absorption, are deemed safe for use during pregnancy.
  • In the third trimester, acne may worsen, and women with conditions like PCOS may experience more severe acne.
  • Risks associated with beta-carotene and vitamin A supplements are highlighted, as patients need to be cautious of teratogenic risks from Vitamin A, particularly in high doses.
  • Zinc is generally recommended for pregnant patients and is considered safe in doses of 75 mg/day.
  • Consideration of the trimester is important for the safety of medication use during pregnancy, and interdisciplinary communication with OB/GYN is crucial when managing these patients.
  • If patients inadvertently use topical retinoids during pregnancy, the evidence suggests low risks of serious adverse outcomes, yet caution is warranted.
  • McMullan P, Yaghi M, Truong TM, Rothe M, Murase J, Grant-Kels JM. Safety of dermatologic medications in pregnancy and lactation: An Update - Part I: Pregnancy. J Am Acad Dermatol. 2024 Jan 25:S0190-9622(24)00109-9.
  • Marita Yaghi, Patrick McMullan, Thu M Truong, Marti Rothe, Jenny Murase, Jane M Grant-Kels. Safety of dermatologic medications in pregnancy and lactation: An Update - Part II: Lactation. J Am Acad Dermatol. 2024 Jan 25:S0190-9622(24)00109-9.
  • Akash Rau, Jonette Keri, Jenny E Murase. Management of Acne in Pregnancy. Am J Clin Dermatol. 2024 Mar 7.
  • Nussbaum, R.Clin Derm 2006; 24:133-141.
  • Bechstein SK, Ochsendorf F. Hautarzt. 2017 Feb;68(2):111-119.
  • Ömer Kutlu, Ayşe Serap Karadağ, et al. Acne in pregnancy: A prospective multicenter, cross-sectional study of 295 patients in Turkey. Int J Dermatol. 2020 Sep;59(9):1098-1105.
  • Ly S, Kamal K, Manjaly P, Barbieri J, Mostaghimi A. Treatment of Acne Vulgaris during Pregnancy and lactation: A Narrative Review, Dermatol Ther 2023 Jan; 13(1):115-130.
  • Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy J Am Acad Dermatol. 2014 Mar;70(3):401.e1-14; quiz 415.
  • Trivedi, N.A ., J. Postgrad Med. 2011:57(2):91-5.
  • Tuffanelli, DL. Ach Dermatol 1982;118(11):876.
  • Selcert, D. Otocerebral anomalies associated with topical tretinoin use. Brain Dev. 2000;22(4):218-20.
  • Autret E et al. Lancet 1997;350(9074):339.
  • Zhang M, Goyert G, Lim HW. Folate and phototherapy: What should we inform our patients? J Am Acad Dermatol. 2017 Nov;77(5):958-964.
  • Zacchè MM1, Caputo L, Filippis S, Zacchè G, Dindelli M, Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol. 2009 Aug;25(8):508-13.
  • Pezza M, Carlomagno V, Casucci G. Inositol and acne. G Ital Dermatol Venereol. 2015 Dec;150(6):649-53.
  • Soana K Motuhifonua, Luling Lin, Jane Alsweiler, Tineke J Crawford, Caroline A Crowther. Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. Cochrane Database Syst Rev. 2023 Feb.